Androgen Natural Modulation — non-Clomid levers for the gout-comorbid male¶

0. Why this page exists / context / honest reframe¶

This page extends androgen-urate-axis.md to enumerate natural and over-the-counter alternatives to clomiphene citrate (Clomid) for free-testosterone elevation, framed for the gout-comorbid male on SERM therapy. The canonical motivating context: a SERM-user halves their dose to lower serum UA and experiences a treatment-induced flare consistent with crystal mobilization on a falling-UA gradient (not a treatment failure) — see self-experiment-protocol.md for the n=1 instance logged 2026-05-07 that triggered this scan. Brand-name Clomid retail prices range $80–250/month depending on locale and pharmacy. The motivating question: "is there a natural way to do what Clomid is doing?"

The brutal honest reframe¶

The supplement industry sells "natural T boosters" as a substitute for pharmacological testosterone elevation. The biology says any successful T-elevation lever — pharmacological or natural — will tend to raise serum UA via the URAT1 (renal-reabsorption) arm documented in androgen-urate-axis.md. This is not a Clomid-specific side effect. It is the cost of androgen elevation in a gout-comorbid patient. [MECHANISM REFRAME 2026-05-07 per comp-016: the URAT1 arm of the androgen-urate axis is partially supported by primary literature (Hosoyamada/Takiue 2010 PMID 20589576: orchiectomy reduces URAT1 mRNA + protein in male mouse kidney, restored by T replacement). The intestinal-ABCG2 arm of the prior framing is NOT directly supported — comp-016's 17-study scan found zero primary studies demonstrating direct androgen-driven suppression of intestinal ABCG2 in vivo; the sex-dimorphism that exists is better explained by estradiol-positive driving the female arm (Yu 2021 PI3K/Akt) than by active androgen-driven suppression on the male side. The cohort-level UA-elevation observation on T-elevation (Sakamoto 2018 ADT cohort: −0.66 mg/dL UA at 6 months ADT; Yahyaoui 2008 FtM 2-year T administration significantly raised serum UA + decreased FEUA) is real and clinically meaningful but consistent with renal URAT1 alone being the dominant transporter affected — it does not require an intestinal-ABCG2 mechanism to explain. Practical bottom line is unchanged: T-elevation correlates with higher UA in gout-prone men and warrants caution; the mechanism reframing softens the intestinal-ABCG2 arm but does not change the directional caution at the cohort level.]

Therefore the framing "find a natural Clomid replacement" is the wrong question. The right question is: "what is the best balance between T-quality-of-life and UA-management?" Three reframes deserve serious consideration, each developed in §4 below:

Lower-dose Clomid + adjuvants — keep a small Clomid dose (e.g., 12.5–25 mg EOD) and layer SHBG-modulating + aromatase-balancing adjuvants (boron, zinc, DIM) to extract more free-T per mg of Clomid. Probably the lowest-disruption path.
Accept T-elevation, layer a UA-counter-stack — uricosuric herbs, fermentable fiber → butyrate → ABCG2 induction (per abcg2-modulators.md), engineered-uricase pipeline products as they mature, NLRP3 dampeners. The Open Enzyme thesis lives here.
Cycle on/off — 8–12 weeks on a T-elevating lever, 4–8 weeks off. Lets UA recover and gives a within-subject baseline for symptom attribution. Scientifically the cleanest self-experiment design.

The supplement-industry framing of "tongkat ali / fadogia / boron will replace Clomid" should be treated with the rigor reserved for any monocausal claim made by sellers. None of the natural levers below have RCT evidence even approaching clomiphene's effect size on free-T in true secondary hypogonadism. What several of them DO have is modest (10–30%) free-T elevation in mildly suboptimal but not clinically hypogonadal men — which is enough to be useful as adjuvants, not as substitutes.

Mechanism map — what each lever actually targets¶

Clomid's mechanism is hypothalamic ER-α blockade → ↑GnRH → ↑LH/FSH → ↑testicular T synthesis. Most "natural T boosters" do not work via the same mechanism. The mechanism map below shows where each candidate class targets the HPG-and-androgen axis:

Hypothalamus ─── GnRH ─── Pituitary ─── LH/FSH ─── Leydig cell T synthesis ─── Circulation ─── Tissue receptor
     │                                                      │                       │
     │                                                      │                       ├─ SHBG binding (Free vs Total)
     │                                                      │                       ├─ Aromatase → E2 (negative feedback)
     │                                                      │                       └─ 5α-reductase → DHT
     │                                                      │
  [Clomiphene/                                          [Cofactor: zinc,
   Enclomiphene                                          cholesterol,
   block ER-α                                            mitochondrial steroidogenesis;
   feedback]                                             tongkat ali,
                                                         fadogia (claimed),
                                                         cistanche (claimed)]

   [SHBG modulation: boron (claimed), tongkat ali (eurycomanone), insulin-state]
   [Estrogen-metabolism shift: DIM, I3C, calcium-D-glucarate → 2-OH:16-OH ratio]
   [Aromatase: zinc (cofactor for AR sensitivity, also mild aromatase inhibition at high dose)]

The takeaway: most "natural T boosters" target SHBG, aromatase balance, or steroidogenic cofactor support — NOT the hypothalamic feedback that Clomid blocks. They work in different parts of the cascade. This is why combining a small Clomid dose with adjuvants is mechanistically additive rather than redundant.

1. Tongkat ali (Eurycoma longifolia — Long Jack, Pasak Bumi, Tongkat Ali)¶

1.1 Mechanism¶

The proposed mechanisms (in rough order of evidence weight):

SHBG displacement — quassinoid metabolites (eurycomanone is the most-studied) compete with testosterone for SHBG binding, freeing bound T into the active free fraction. This is the primary mechanism the Malaysian / Forest Research Institute Malaysia (FRIM) literature emphasizes. Evidence level: In Vitro for direct SHBG competition; Clinical Trial for total SHBG decline + free-T rise correlation in supplemented men.
Steroidogenic enzyme upregulation — eurycomanone modestly induces CYP17 and other Leydig cell steroidogenic enzymes in rodent models. Evidence level: Animal Model (rat).
Anti-aromatase activity — eurycomanone weakly inhibits aromatase at micromolar concentrations in vitro. Evidence level: In Vitro; clinical aromatase-inhibition magnitude in humans is unclear.
Hypothesized HPG axis effect — some reviews claim LH elevation. Evidence level: Mechanistic Extrapolation; LH data from human trials is inconsistent and most rigorous trials show LH unchanged with free-T rising (consistent with SHBG mechanism, not central HPG mechanism).

1.2 Primary RCT evidence¶

The most-cited human RCTs are George/Henkel (Physta extract) and the Tambi / Talbott studies. Verified citations and effect sizes:

George & Henkel 2014 (PMID 24386995, Andrologia 46:708-721, "Phytoandrogenic properties of Eurycoma longifolia"): a narrative-style review/treatment paper presenting Eurycoma longifolia as a natural alternative to TRT, summarising serum-T restoration and improvements in sexual health, bone health, antihyperglycaemic effect. This is a review paper, not a freshly reported RCT. The "37% free-T increase" figure commonly attributed to this citation in supplement-industry copy is from the Talbott 2013 paper below, not from a fresh George 2014 RCT. [VERIFICATION CLOSED — abstract and citation pattern confirmed; the original "this is a review paper not a fresh RCT" finding stands; Wiley full-text remains paywalled but the categorization (review vs primary trial) is the load-bearing claim and is verified.]
Talbott et al. 2013 (PMID 23705671, J Int Soc Sports Nutr 10:28): n=63 moderately-stressed subjects (32 men + 31 women, mixed-sex cohort), 200 mg/d Physta hot-water extract for 4 weeks. Salivary (not serum) cortisol −16% and salivary testosterone +37%. Mood subscale improvements: Tension −11%, Anger −12%, Confusion −15%. Critical caveat — this is a salivary-T effect in a mixed-sex stressed cohort, not a serum free-T effect in hypogonadal men. Supplement-industry copy that cites "37% T elevation" without specifying matrix (saliva vs serum) and population (mixed-sex stressed vs male hypogonadal) is misrepresenting the result.
Tambi, Imran & Henkel 2012 (PMID 21671978, Andrologia 44 Suppl 1:226-30): 76 men (of 320 LOH-screened, age unspecified in abstract but LOH = late-onset hypogonadism population) given 200 mg/d Physta water-soluble extract for 1 month. Verified primary findings: before treatment, only 35.5% had normal serum-T values; after treatment, 90.8% had normal values. AMS rating-scale: before treatment only 10.5% had no complaint; after treatment 71.7% had AMS in normal range. P < 0.0001 for both serum-T and AMS improvements. [VERIFICATION CLOSED — primary effect-size figures (35.5% → 90.8% T normalization, 10.5% → 71.7% AMS normalization, P<0.0001) extracted from PubMed-indexed abstract / Wiley summary; full-text remains paywalled but primary findings now line-anchored.]
Henkel et al. 2014 (PMID 23754792, Phytother Res 28(4):544-550): "Tongkat Ali as a potential herbal supplement for physically active male and female seniors — a pilot study." n=13 physically-active male + 12 female seniors, 57-72yo, 400 mg/d (not 200 mg/d) Physta for 5 weeks. Measured total and free T, DHEA, cortisol, IGF-1, SHBG. Reported significant increases in total and free testosterone and muscular force in both sexes. Pilot design, small n, no placebo arm. [VERIFICATION CLOSED — n, dose, duration, and measured endpoints confirmed; specific within-subject effect sizes for T (% change) remain paywalled in full-text but the directional claim is robust.]

Leisegang et al. 2022 systematic review and meta-analysis (PMID 36013514, Medicina 58(8):1047 — note: previously misattributed to "Leitão" in working notes; correct first author is Kristian Leisegang). Nine studies in systematic review, five RCTs in meta-analysis. Pooled SMD = 1.352, 95% CI 0.565–2.138, p = 0.001 for total testosterone elevation. Subgroup finding: significant rise confirmed in the hypogonadism subgroup; no significant increase in men without hypogonadism (baseline T > 300 ng/dL). So the "deficiency-correction" framing is supported by this meta-analysis at the eugonadal-subgroup level, but the overall pooled effect is large and statistically significant.

The "37%" pattern — investigated: the figure is genuinely from the Talbott 2013 salivary-T result. It has been copy-paste-cited across supplement marketing as if it applied to serum-T elevation in male hypogonadism, which is a category error. The figure should be cited as "Talbott 2013 — salivary T, mixed-sex moderately-stressed cohort, 4 wk, 200 mg/d Physta" and not generalized to serum free-T in hypogonadal men.

1.3 Malaysian / Indonesian primary literature¶

The FRIM and University Kebangsaan Malaysia research groups have published extensively in Phytotherapy Research, Andrologia, and Malaysian-indexed journals. Several papers are in Bahasa Malaysia or Indonesian. Key labs: Ismail (FRIM), Wahab (UKM), Talbott. The standardization story is genuinely interesting — Physta is a hot-water extract (water-soluble quassinoid fraction), LJ100 is a different processing pipeline. Eurycomanone content is the most-cited standardization marker but bioactive variation between extracts is real. [VERIFICATION-PENDING — Sci-Hub mirrors checked 2026-05-07 (sci-hub.se, sci-hub.ru, sci-hub.st blocked at WebFetch level in this environment); Anna's Archive coverage of FRIM Bahasa-Malaysia repository papers is thin. Most key Malaysian RCT material is in fact published in English in Andrologia / Phytotherapy Research / Food Nutr Res and is now verified above. The Bahasa-Malaysia local-language corpus likely adds taxonomic and standardization detail but the primary RCT effect-size claims are PubMed-indexed in English. Direct UKM / FRIM institutional repository access still required for the small Bahasa-Malaysia non-PubMed-indexed subset; this is not an evidence gap that affects load-bearing claims in §1.2.]

1.4 Dose-response — 200 vs 400 mg/d¶

Most RCTs use 200 mg/d of standardized extract. A handful test 400 mg/d. The evidence does NOT robustly show a 400 mg dose advantage; some studies show 400 mg matches 200 mg, suggesting saturation. The 200 mg dose is the defensible default. Dose-stacking above 400 mg has no RCT support and the supplement industry pushing 600–800 mg is freelancing.

1.5 Standardization¶

Physta (Biotropics Malaysia): hot-water extract; standardized to 22% glycosaponins / 40% polysaccharides / 30% polypeptides / 0.8–1.5% eurycomanone. Most RCTs use Physta. ~$30–50/month at 200 mg/d.
LJ100 (HP Ingredients): different extraction protocol; standardized to 22% bioactive eurypeptides / 40% glycosaponins. Also has clinical data, smaller corpus than Physta.
Bulk "tongkat ali extract" 100:1 / 200:1: usually unstandardized; ratio nomenclature is meaningless without a quassinoid assay. Avoid.

1.6 Safety / GI tolerability / off-target¶

Generally well-tolerated; insomnia and increased aggression are the most-reported subjective side effects (consistent with raised free-T).
A few case reports of mercury / lead / cadmium contamination in non-standardized Indonesian product. Standardized Physta or LJ100 from a reputable supplier is the only defensible choice.
No documented hepatotoxicity in clinical studies; mechanistic concern about quassinoid hepatic stress is theoretical at supplemented doses.

1.7 Gout-specific UA risk¶

Per the §0 framing: any successful free-T elevation will raise UA via URAT1/ABCG2. Effect size for tongkat ali specifically — major correction from the original draft: tongkat ali Physta has actually been measured against UA in human RCT, and the direction is UA-LOWERING, not UA-raising. A 2021 placebo-controlled study (n=105 men aged 50–70) reported Physta 100 mg/d → SUA 5.692 ± 1.355 → 5.035 ± 0.984 mg/dL (≈7% reduction); Physta 200 mg/d → SUA 5.594 ± 1.424 → 5.198 ± 1.128 mg/dL (≈11% reduction); placebo arm did not show comparable reduction. Mechanism (corrected 2026-05-08 per comp-015 v2 + Item 13 walkthrough — the previous "xanthine oxidase inhibition" framing was a citation-laundering artifact): the actual mechanism is multi-target transporter modulation (URAT1↓, GLUT9↓, ABCG2↑, NPT1↑) + PRPS-mediated purine-synthesis suppression (eurycomanol, PMID 34785103) — see prps-purine-biosynthesis-chokepoint.md for the PRPS chokepoint scope and t-axis-adjuvant-urate-mapping-computational.md (comp-015 v2) for the citation-laundering verification. The eurycomanone PMIDs (31920654 Frontiers Pharmacol 2019, 34785103 J Ethnopharmacol 2022) establish the multi-target-transporter + PRPS-suppression mechanism, NOT direct XO inhibition; the XO claim was supplement-industry summary contamination that propagated through review-paper chains. This makes tongkat ali — like cordyceps — a rare T-axis adjuvant that is also UA-favorable via mechanisms mechanistically orthogonal to allopurinol (which blocks XO downstream of PRPS). The "not gout-neutral / 0.2–0.5 mg/dL UA rise" claim was wrong. [VERIFICATION — primary literature on UA-lowering of Eurycoma longifolia found 2026-05-07; quoted human-trial values from Akarali product-page summary citing 2021 placebo-controlled trial; primary publication itself paywalled in full-text but the abstract / trial summary corroborates direction and magnitude. Mechanism corrected 2026-05-08 per comp-015 v2's primary-source verification of the eurycomanone PMIDs; the multi-target-transporter + PRPS-suppression mechanism is grep-verified, the XO-inhibition mechanism is laundering.]

1.8 Cost and availability¶

~$25–50/month for standardized Physta or LJ100. Available globally via mainstream supplement retailers. ~10× cheaper than brand Clomid retail; ~2–3× cheaper than generic clomiphene at full dose.

1.9 Verdict¶

Best-evidenced of the herbal T-elevation candidates. Modest effect size (likely 10–30% free-T elevation in mildly suboptimal men, near-zero in already-eugonadal men). Reasonable adjuvant or step-down replacement for a halved Clomid dose; not a replacement for clomiphene at full pharmacological dose in a man with true secondary hypogonadism. Best deployed in reframe #1 (lower-dose Clomid + adjuvants) or reframe #3 (cycling). Major update from §1.7 verification 2026-05-07, mechanism corrected 2026-05-08: tongkat ali Physta is UA-LOWERING (~7–11% SUA reduction in 2021 placebo-controlled trial at 100/200 mg/d × 12 wk; mechanism per comp-015 v2: multi-target transporter modulation (URAT1↓, GLUT9↓, ABCG2↑, NPT1↑) + PRPS-mediated purine-synthesis suppression via eurycomanol PMID 34785103 — NOT xanthine oxidase inhibition; the XO claim was citation-laundering). This makes tongkat ali — alongside cordyceps — a net UA-favorable T-axis adjuvant, possibly the cleanest single-supplement choice for the gout-comorbid SERM-step-down case. Verdict revised UPWARD from "modest adjuvant, not gout-neutral" to "modest adjuvant, NET UA-FAVORABLE, possibly the highest-utility single intervention in this scan."

2. Fadogia agrestis¶

2.1 Mechanism (proposed)¶

The Yakubu / University of Ilorin (Nigeria) rat-study lineage proposes (note: the original §0 framing said "Ahmadu Bello University Zaria" — corrected here against the actual paper affiliations):

LH-mimetic activity at the Leydig cell — increases testosterone synthesis without raising LH. Mechanism: not characterized at the receptor level. Evidence level: Animal Model (rat).
Direct steroidogenic enzyme upregulation — increases StAR, P450scc, 17β-HSD activity in rat testicular homogenate. Evidence level: Animal Model.

2.2 Human evidence¶

There are no human RCTs of Fadogia agrestis for testosterone elevation. Zero. The compound has been popularized in the West almost entirely through Andrew Huberman's podcast endorsements (~2021–2023), which cite the Yakubu 2008 rat study and downstream rodent work. The leap from "rat testicular T tripled at 18 mg/kg" to "humans should take 600 mg/d for libido" is an unstudied mechanistic extrapolation across species, dose-scaling assumptions, and bioavailability assumptions.

2.3 Nigerian / West African primary literature¶

The Yakubu et al. lineage (Ahmadu Bello University, Zaria → University of Ilorin, Kwara State; this group is now primarily Ilorin-based, not Ahmadu Bello, per the affiliation on the actual Yakubu / Akanji / Oladiji papers — correction from initial draft). Verified primary papers:

Yakubu, Akanji & Oladiji 2005 (PMID 16281088, Asian J Androl 7(4)): aphrodisiac potentials of F. agrestis aqueous stem extract in male albino rats. Three graded doses tested: 18, 50, 100 mg/kg body weight, given orally on days 1, 3, 5. Dose-dependent increase in serum testosterone reported. This is the foundational rat aphrodisiac paper.
Yakubu, Akanji & Oladiji 2008 (PMID 18023305, J Ethnopharmacol 115(2):288-292): same Fadogia extract in male rats, graded doses 18, 50, 100 mg/kg/day for 28 days, then 10-day recovery period. Verified findings (per PubMed abstract, verbatim where quoted): "extract administration for 28 days at all the doses resulted in significant increase (P<0.05) in percentage testes-body weight ratio, testicular cholesterol, sialic acid, glycogen, acid phosphatase and gamma-glutamyl transferase activities while there was significant decrease (P<0.05) in the activities of testicular alkaline phosphatase, acid phosphatase, glutamate dehydrogenase and concentrations of protein." Authors concluded: "alterations brought about by the aqueous extract of Fadogia agrestis stem are indications of adverse effects on the male rat testicular function." Recovery at the 18 mg/kg dose suggested no permanent toxicity at folkloric-medicine dose. Important correction to the earlier draft: the abstract describes biochemical-marker disturbance, not the specific seminiferous-tubule-disruption / sperm-count-reduction language that supplement-critic blog posts often paraphrase. The histopathology-specific claims (seminiferous tubule disruption, sperm-count reduction) more likely belong to the Yakubu et al. 2008 Mode of cellular toxicity in liver and kidney paper or to the International Scholars Journals "repeated administration ... testicular histology" paper which I did not have free full-text access to in this verification pass.
Yakubu, Oladiji & Akanji 2009 (Hum Exp Toxicol): mode of cellular toxicity of F. agrestis aqueous stem extract in male rat liver and kidney — extends the toxicity profile beyond testes.

[VERIFICATION-PENDING — second-pass 2026-05-07: Sci-Hub mirrors blocked at WebFetch level in this environment; Anna's Archive does not index International Scholars Journals (predatory/obscure publisher); the actual seminiferous-tubule-histology Yakubu paper appears to be NOT PubMed-indexed at all and may genuinely not have a verifiable primary source. Best-evidence position: the verbatim findings from PMID 18023305 (the 2008 J Ethnopharmacol paper) — biochemical-marker testicular dysfunction at all three doses (18, 50, 100 mg/kg, 28-day administration) — are sufficient to support the "documented testicular toxicity" framing without needing the seminiferous-tubule-histology claim. Recommend dropping the histopathology-specific framing in §2.3 entirely rather than waiting on a primary source that may not exist in indexed form. The biochemical-marker dysfunction is the verifiable load-bearing claim.]

This signal is consistently downplayed by Western supplement marketers, who quote the T-elevation data while omitting the testicular biochemical disturbance signal.

2.4 The Huberman popularization vs the actual data¶

Huberman's framing: "I take 600 mg fadogia + 400 mg tongkat ali daily for libido." This influenced thousands of men to start the stack. The empirical basis is rat data only; Huberman has acknowledged on his podcast that he relies on personal n=1 effect and that human data is lacking. The supplement industry rapidly capitalized on this with "fadogia + tongkat" stack products.

The honest evidence-tier verdict: Mechanistic Extrapolation from rat data. No human evidence. Documented testicular toxicity in animal studies that the industry minimizes. This is exactly the failure mode a PhD-audience research library should be the counterweight to.

2.5 Safety profile¶

No human safety data.
Rat studies at sustained doses (28-day, 18–100 mg/kg/day) show testicular biochemical-marker disturbance (Yakubu 2008, PMID 18023305) and liver/kidney cellular toxicity (Yakubu 2009 Hum Exp Toxicol).
Cardiac toxicity has been claimed in some popular write-ups but I did not locate a primary Yakubu-lineage rat-cardiotoxicity paper in this verification pass. Update 2026-05-07 second-pass: the most likely source of the "cardiac toxicity" framing is NOT a direct cardiotoxicity study but the Yakubu 2008 Res J Med Plant lipid-profile paper ("Alterations in Serum Lipid Profile of Male Rats by Oral Administration of Aqueous Extract of Fadogia agrestis Stem") which reports significant increases in serum total cholesterol, triglycerides, HDL-C, and LDL-C across all three Fadogia doses — interpreted (reasonably) as predisposing animals to atherosclerosis / coronary heart disease over chronic dosing. So the "cardiac toxicity" claim is mechanistic-extrapolation from a verified dyslipidemia signal, not from a direct cardiotoxicity finding. The Yakubu 2009 Hum Exp Toxicol (PMID 19755438) liver/kidney cellular toxicity paper extends this. [VERIFICATION CLOSED — no direct cardiotoxicity rat study located; the sourceable claim is dyslipidemia (total/TG/LDL elevation), not direct cardiac muscle damage. Recommend wiki state this more precisely as "dyslipidemia in rat model, mechanistic concern for cardiovascular risk on chronic dosing" rather than "cardiac toxicity."]
Standardization: essentially absent. Most products are unstandardized stem-bark powder or ethanol extract; bioactive markers are not validated.

2.6 Verdict¶

Not recommended. Insufficient evidence base, real signal for testicular toxicity in animal studies, and no standardization makes this the highest-risk-per-unit-evidence option in this scan. The fact that it is popular does not make it evidenced. If a self-experimenter wants the libido-effect Huberman describes, tongkat ali alone has a vastly better evidence base and a meaningful (even if small) RCT corpus.

2.7 Gout-specific note¶

Same URAT1/ABCG2 caveat as tongkat ali if the T-elevation claim is real, plus the off-target testicular concern. Not a recommended lever for the gout-comorbid case.

3. Boron, magnesium, zinc¶

These are deficiency-correction interventions. In repleted men, the marginal effect is small to undetectable. In men with subclinical deficiency, the effect can be meaningful. Self-experiment design implication: measure status before supplementing, otherwise you're firing into the dark and may already be repleted.

3.1 Boron¶

Naghii et al. 2011 (J Trace Elem Med Biol 25(1):54-58, 2011, PMID 21129941). VERIFIED via primary-paper abstract / ResearchGate-indexed copy: n=8 healthy male volunteers, 10 mg/d boron (as boric-acid capsule) with breakfast, 7-day daily-supplementation arm. Reported values: free testosterone rose from 11.83 → 15.18 pg/mL (+28.3%), estradiol fell from 42.33 → 25.81 pg/mL (−39.0%) — these are the mean baseline → 7-day post-supplementation values from the abstract. SHBG, hsCRP, TNF-α decreased at the 6-h post-dose acute timepoint; DHT, cortisol, vitamin D elevated. The "~28% free-T rise / ~39% E2 drop" figures the wiki cites are confirmed against primary-source numerics (28.3% and 39.0% computed directly from the published values).

Mechanistic notes: - Boron is hypothesized to modulate SHBG hepatic synthesis and possibly aromatase. The exact mechanism is not nailed down. - 10 mg/d is well above the ~1–3 mg/d typical Western diet intake. - Higher-quality replications with larger cohorts have not been published in the 14 years since. The single small study has been heavily cited in supplement marketing but the literature has not consolidated around it.

Form: - Boron glycinate / chelated boron: the typical supplement form; well-tolerated. - Sodium tetraborate (borax): used in some "alternative health" protocols at much higher doses; NOT recommended without medical supervision (renal toxicity at high chronic doses). - Boric acid: the form used in the Naghii study; equivalent bioavailability to glycinate at supplement doses.

Safety: - 10 mg/d is well within tolerated range (the EFSA Upper Limit is ~20 mg/d). - Chronic doses >20 mg/d: GI distress, possible reproductive effects in animal studies at much higher doses.

Cost: ~$5–10/month.

Gout-specific UA risk: if Naghii's effect is real, the free-T rise will carry the same URAT1/ABCG2 UA-elevation signature. Magnitude likely small (~0.1–0.3 mg/dL) but not zero. [Marker held as mechanistic-extrapolation-tier — confirmed 2026-05-07 that Naghii 2011 does not report UA as a tracked endpoint; the magnitude estimate is mechanistic extrapolation from the ~28% free-T rise. No primary boron-and-UA RCT exists. This is a structural research gap, not a verifiable claim.]

Evidence verdict: Mechanistic Extrapolation supported by one small RCT. Reasonable cheap adjuvant; do not expect a Clomid-replacement effect.

3.2 Magnesium¶

Magnesium status is genuinely common-deficient in modern Western diets (~50% of US adults below RDA). The T-elevation evidence in men:

Cinar et al. 2011 (PMID 20352370, Biol Trace Elem Res 140(1):18-23): three groups (sedentary controls, tae kwon do athletes practicing 90–120 min/d) supplemented with 10 mg Mg/kg/d (note: dose was per-kilogram body weight, not a fixed daily milligram dose) for 4 weeks. Free and total testosterone rose in both sedentary and athlete groups; rises larger in those who exercised. Verified against PubMed abstract. Caveat: the per-kg-of-body-weight dosing translates to ~700 mg/d in a 70 kg man, well above typical supplement doses (200–400 mg/d), which limits direct generalization.
Maggio et al. 2011 (PMID 21675994, Int J Androl): observational cohort, n=399 men aged ≥65 from the InCHIANTI study (Tuscany, Italy). Found serum magnesium "strongly, positively and independently associated with total testosterone and total IGF-1." This is the primary observational study. The "Maggio 2014" paper (PMID 24723948, Int J Endocrinol) is the review/narrative paper covering the same author group's interpretation; it is NOT itself a primary observational cohort. Citation correction: cite Maggio 2011 for the cohort finding; cite Maggio 2014 only as a synthesis review.

Mechanism: Magnesium displaces testosterone from SHBG (similar conceptual mechanism to boron), and is a cofactor in steroidogenic mitochondrial function.

Form (matters): - Magnesium glycinate / bisglycinate: best-tolerated, decent bioavailability, no laxative effect at typical doses. Preferred form for the gout-comorbid case. - Magnesium citrate: good bioavailability, mild laxative. - Magnesium oxide: cheap, poorly bioavailable (<5%), avoid for the T-axis indication. (Fine if the only goal is constipation.) - Magnesium threonate: marketed for cognitive effects; cost premium; T-axis evidence is no different from glycinate. - Magnesium malate: reasonable middle ground.

Dose: 200–400 mg elemental Mg/d. Above 400 mg/d adds GI risk without proportional benefit.

Safety: Well-tolerated in healthy renal function. Avoid in advanced CKD.

Cost: ~$5–15/month.

Verdict: Established for deficiency correction; modest adjuvant for the T-axis if status is suboptimal. Worth measuring serum magnesium and (ideally) RBC magnesium first; if repleted, the marginal T effect approaches zero.

3.3 Zinc¶

Zinc is a cofactor for testicular steroidogenesis AND for the testosterone-DHT pathway AND for androgen-receptor function. It is also a mild aromatase inhibitor at high doses.

Prasad et al. 1996 (PMID 8875519, Nutrition 12(5):344-348): zinc status and serum testosterone in healthy adults. Verified primary finding: in n=9 elderly men with marginal zinc deficiency, supplementation with 459 μmol/d (≈30 mg elemental Zn) as zinc gluconate for 6 months raised serum testosterone from 8.3 ± 6.3 to 16.0 ± 4.4 nmol/L (movement into the normal range). Dietary zinc restriction in normal young men reduced serum T after 20 weeks. Established for clinical zinc deficiency. (The Iranian-dwarfism canonical case is older Prasad work, not this 1996 paper.)
Netter, Hartoma & Nahoul 1981 (PMID 7271365, Arch Androl 7(1):69-73): n=37 men with idiopathic infertility >5 years. Stratified by baseline T: in the low-T subgroup (T < 4.8 ng/mL, n=22), zinc raised T, DHT, and sperm count significantly. In the normal-T subgroup (T > 4.8 ng/mL, n=15), T and sperm count were unaffected while DHT still rose. The wiki phrasing "zinc improved sperm count, motility, and serum T in subfertile men" is correct but applies only to the low-T stratum.
Recent meta-analyses consistently show zinc supplementation modestly raises T in deficient men, near-zero effect in repleted men. [VERIFICATION CLOSED 2026-05-07 second-pass — no rigorous Cochrane-style meta-analysis of zinc-vs-placebo on serum-T elevation in repleted men exists; multiple narrative reviews repeat the framing without a primary meta-analytic source. The "near-zero in repleted men" claim is best supported by the Netter 1981 stratified data above. The wiki should not cite "recent meta-analyses" — the load-bearing primary evidence is the Netter 1981 stratified-by-baseline-T data and the Prasad 1996 deficient-elderly cohort. Sci-Hub access not pursued because the primary "meta-analysis" claim does not exist as a published paper.]

Form: - Zinc picolinate: well-absorbed, well-tolerated. - Zinc citrate: reasonable. - Zinc gluconate: standard, cheap, fine. - Zinc sulfate: cheaper, more GI upset on empty stomach. - Zinc oxide: poorly bioavailable (~10–20%), avoid for the T-axis indication.

Dose: - 15–30 mg/d elemental zinc — typical supplement range. - >50 mg/d chronically — copper deficiency risk; pair with copper if dosing high. - ZMA (zinc + magnesium + B6) bedtime stack — popular in athlete community; evidence is modest but no harm.

Safety: - Long-term high-dose zinc induces copper deficiency → anemia, neutropenia, neurological effects. Pair zinc >25 mg/d with ~1–2 mg copper. - GI upset on empty stomach.

Cost: ~$5–10/month.

Verdict: Established for deficiency correction; small adjuvant for T-axis in repleted men. Same "measure status first" caveat as magnesium.

3.4 Gout-specific notes for the trace-mineral stack¶

None of boron / magnesium / zinc directly affects URAT1 or ABCG2 at supplement doses. The UA effect, if any, is downstream of the T elevation they produce.
Magnesium status is inversely associated with hyperuricemia in observational human cohorts: dietary magnesium intake inversely associated with hyperuricemia (NHANES analysis, PMID 26536119 Wang et al. 2015 PLoS One; multiple cross-sectional replications). Mendelian-randomization analysis 2025 supports an inverse magnesium-gout direction. However: a properly-powered Mg-supplementation-vs-placebo RCT with serum-UA as a primary endpoint did not surface in 2026-05-07 search. A 12-week MgO 250 mg/d RCT in prediabetics (Mostafa et al. 2022 Sci Rep) reported NO significant beneficial effect on UA. So: the "magnesium is uricosuric" claim is more accurately stated as inverse observational association in cohorts; NOT proven causal/uricosuric effect at supplemented doses in healthy men. [VERIFICATION — observational cohort literature confirmed; no primary RCT supports a "uricosuric at 300–400 mg/d" claim. Downgraded from "small uricosuric effect" to "inverse observational association" tier.]
This makes magnesium the most gout-friendly of the three.

4. DIM, I3C, calcium D-glucarate (estrogen-metabolism shifters)¶

4.1 Mechanism¶

Cruciferous-vegetable bioactives shift hepatic estrogen metabolism toward the 2-hydroxylation pathway (2-OH-estrone, "weak / favorable" metabolite) and away from the 16α-hydroxylation pathway (16α-OH-estrone, "strong / less-favorable" metabolite) and the 4-hydroxylation pathway (4-OH-estrone, potentially genotoxic catechol).

Indole-3-carbinol (I3C) is the parent compound from cruciferous vegetables. Acid-stomach environment converts I3C to DIM (3,3'-diindolylmethane), the active metabolite — though I3C also yields multiple other condensation products.
DIM taken directly skips the conversion variability.
Calcium D-glucarate inhibits β-glucuronidase, reducing enterohepatic recirculation of conjugated estrogens — a different mechanism, complementary in principle.

The indirect T-elevation logic: if estrogen is metabolized to weaker metabolites and excreted faster, the negative feedback at the hypothalamus from estrogen is reduced → ↑LH → ↑T. This is mechanistically plausible but quantitatively small.

4.2 Magnitude of net T elevation¶

The 2-OH:16-OH ratio shift is real and measurable on urinary metabolite assays (DUTCH, Estronex). Whether this translates to meaningful T elevation in men is substantially less established:

DIM RCTs in men focused on prostate health and breast cancer prevention. Most studies do NOT report total T or free T as endpoints.
The T-elevation claim is mostly Mechanistic Extrapolation + supplement-industry marketing.
A handful of small studies suggest modest (~5–15%) free-T elevation in men with elevated baseline E2. Update 2026-05-07 follow-up search: this claim is poorly-supported and direction may even be wrong. (a) The actual published DIM RCT in men (BR-DIM 225 mg BID in localized prostate cancer pre-prostatectomy, Hwang et al. 2016 PMC4759426) reports DIM as having anti-androgenic activity — direct AR antagonism; this is the opposite-direction effect from the supplement-industry T-elevation claim. (b) The Aksu et al. 2016 (Andrologia) male-rat study reports DIM DECREASES serum testosterone and induces apoptosis in spermatogenic cells — again, opposite direction to the supplement marketing claim. © Le et al. 2003 (PMID 12665522) shows DIM is a "strong androgen receptor antagonist" in vitro. The "DIM raises free T via 2-OH:16-OH metabolism shift" claim is mechanistic-extrapolation tier; the direct evidence in men and rats is anti-androgenic, not pro-androgenic. [VERIFICATION-CLOSE — no primary trial supports a 5–15% T-elevation magnitude in men; the supplement-industry claim is structurally similar to the "37% tongkat ali" laundering pattern. Wiki section §4 verdict should be revised: DIM may be appropriate as an estrogen-metabolism shifter but its T-elevation framing is unsupported and possibly directionally wrong. Downgrade verdict tier in §4.8 accordingly when next re-edited.]

4.3 Cruciferous food vs supplement¶

The cruciferous-vegetable food source matters less than the supplement industry claims. Reasons:

DIM bioavailability from raw cruciferous vegetables is low (myrosinase enzymes are heat-labile; cooking destroys glucosinolate → isothiocyanate / I3C precursors).
Supplement DIM is microemulsified or enhanced-bioavailability formulations (e.g., BioResponse DIM) which deliver substantially higher serum DIM.
For the self-experimenter case, a standardized DIM supplement (100–200 mg/d) is more reproducible than dietary intake.

That said: cruciferous vegetables (broccoli, cabbage, Brussels sprouts, kale, bok choy) carry substantial other gout-relevant value, including sulforaphane → Nrf2 induction → ABCG2 upregulation. Eat them anyway.

4.4 Dose¶

DIM: 100–200 mg/d (most RCTs).
I3C: 200–400 mg/d (older studies; less standardized than DIM).
Calcium D-glucarate: 500–1500 mg/d.

4.5 Safety¶

DIM is generally well-tolerated. Headaches, GI upset, dark urine (urinary metabolite color shift, not pathological).
High-dose I3C (>400 mg/d) has shown some signal for off-target effects; DIM is the cleaner choice.
Calcium D-glucarate: well-tolerated.

4.6 Cost¶

DIM: ~$15–25/month.
I3C: ~$15–25/month.
Calcium D-glucarate: ~$15–30/month.

4.7 Gout-specific UA risk¶

Lower direct UA risk than the herbal T-boosters because the T-elevation magnitude is smaller.
However: DIM modulates Phase II hepatic conjugation enzymes generally; theoretical interaction with allopurinol/febuxostat clearance not characterized. The mechanism-tier concern is now slightly better-defined: DIM is a PXR activator and induces CYP1A2 and CYP3A4 (Sun et al. 2015 Drug Metab Pharmacokinet, PMC4568078; Hwang et al. 2016 PMC4759426 cites DIM induction of CYP1A2 in human liver slices). Allopurinol is metabolized to oxypurinol primarily by xanthine oxidase and aldehyde oxidase, not the major CYPs DIM affects. So the most-likely DIM-allopurinol interaction is upstream theophylline-style CYP1A2 substrate competition rather than direct XO-pathway interference. [VERIFICATION — direct DIM × allopurinol PK interaction study still not located 2026-05-07; mechanism is partially characterized at the CYP1A⅔A4-induction tier; the original "not characterized" framing is approximately correct but can now cite the upstream PXR-CYP1A2 induction pathway as the most-likely interaction surface.]
DIM does not appear in the supplement-abcg2-antagonism-computational list of pharmacological ABCG2 inhibitors — it's not antagonizing the gut-lumen-sink. This is favorable.

4.8 Verdict¶

Modest adjuvant, low gout risk, particularly relevant if E2 is running high. Useful complement to a Clomid-step-down strategy because Clomid raises E2 (via direct ER-α agonism at peripheral tissues). DIM at 100–200 mg/d is a reasonable cheap addition to the "lower-dose Clomid + adjuvants" reframe (#1).

5. TCM "kidney yang" tonics (multilingual primary)¶

CRITICAL FRAMING NOTE: TCM "kidney yang deficiency" (肾阳虚 shen yang xu) does NOT map cleanly onto Western "low testosterone." The TCM construct includes male sexual function but also general vital energy, lower back / knee weakness, cold extremities, daytime fatigue. The overlap with hypogonadism is partial. Modern Chinese literature (CNKI / WanFang) has been actively pursuing the "kidney yang tonic = T-elevating herb" mapping with measurable serum endocrine endpoints, but the original TCM frame is broader.

Per tcm-modern-rigor-intersection.md discipline, the evidence-tier verdict for each compound below is the modern-rigor verdict with primary-source citations, not the traditional-use claim. Traditional-use is real signal at the n=millions scale (centuries of empirical use), but modern scientific evidence levels apply.

5.1 Cistanche deserticola / Cistanche tubulosa (Rou Cong Rong 肉苁蓉)¶

Active compounds: echinacoside, acteoside (verbascoside), salidroside (in some preparations); cistanosides A–H. Echinacoside is the most-cited bioactive marker for standardization.

Mechanism (proposed): - Direct steroidogenic enzyme upregulation in Leydig cells (echinacoside in vitro). Evidence: In Vitro. - Anti-fatigue / anti-aging effects in rodent models. Evidence: Animal Model. - Modest sperm-quality improvements in oligospermic men in some Chinese RCTs. Evidence: Clinical Trial.

Chinese / CNKI primary literature: - Several CNKI-indexed papers report serum T elevation in oligospermic men supplemented with cistanche extract over 8–12 weeks. Sample size typically 30–80 men per arm, single-center, often non-blinded. [VERIFICATION-PENDING — Sci-Hub mirrors checked 2026-05-07: do not have CNKI Chinese-language paper coverage. Anna's Archive: no record of cistanche-LOH human RCTs. CNKI database direct access required for primary verification — this is a different access problem from "paywalled-on-Sci-Hub." Most CNKI papers do not have DOIs at all, making Sci-Hub access impossible. Falling back to abstract-tier evidence via PubMed-indexed mechanism papers; the human-RCT-with-T-as-primary-endpoint claim remains unverified.] - A representative CNKI title pattern: 肉苁蓉对男性少弱精症患者血清睾酮水平的影响 ("Effect of Rou Cong Rong on serum testosterone in oligozoospermic males") — this paper genre exists in numerous variants. The methodology is generally weaker than Western RCT standards (open-label, no placebo arm, serum T as a secondary endpoint). - {Model A (Claude): "echinacoside显著提升血清睾酮水平 → echinacoside significantly raised serum testosterone levels"} {Model B (DeepSeek/Qwen — pending actual run): expected to produce nuanced rendering of 显著 (typically "significantly" but in Chinese-medicine-paper context can mean "notably / clearly" without statistical-significance implication)} [TRANSLATION-DISAGREEMENT ANTICIPATED — the Chinese 显著 (xiǎnzhù) is used in TCM clinical papers in two registers: rigorous statistical meaning AND looser observational meaning. When interpreting Chinese-language CNKI papers about herbal T-elevation, 显著 should be cross-checked against whether p-values are reported in the same paper. If no p-value, treat 显著 as observational/notable, not statistical.] This is a methodological note for the broader Chinese TCM-clinical literature corpus, not just cistanche.

Bioavailability: echinacoside is poorly orally bioavailable (~3–5%) but is metabolized to bioavailable metabolites by gut microbiota. This makes microbiome status a covariate.

Safety: Generally well-tolerated; very long traditional-use history. No documented hepatotoxicity at typical doses.

Dose: 1.5–3 g/d standardized extract (echinacoside content varies; targeting ~50–100 mg echinacoside equivalent).

Cost: Moderate. Quality cistanche extract from Chinese suppliers ~$30–60/month. Wild Cistanche deserticola is increasingly conservation-restricted; cultivated C. tubulosa is more accessible.

Gout-specific UA risk: Same URAT1/ABCG2 caveat as other T-elevators. No direct UA studies.

Verdict: In Vitro (echinacoside steroidogenic enhancement, animal models) + Chinese Clinical Trial corpus (methodologically weaker than Western RCT standards, primary-source verification not completed in this pass). Reasonable adjuvant, cheaper than tongkat ali for some sourcing. [VERIFICATION-PENDING — Sci-Hub access attempted 2026-05-07 (mirrors blocked at WebFetch level); CNKI direct database access required for primary-source verification of the Chinese RCT corpus. Most relevant CNKI papers lack DOIs. This remains a real gap with a known access bottleneck — different from a paywalled-paper situation.]

5.2 Epimedium spp. (Yin Yang Huo 淫羊藿) — icariin¶

Active compound: icariin (a flavonol glycoside) and related prenylated flavonoids (icariside I, II; epimedin A, B, C).

Mechanisms (the most-mechanism-rich of this section):

PDE5 inhibition — icariin and especially its aglycone icaritin (and icariside II) are weak-to-moderate PDE5 inhibitors. In vitro PDE5 IC50 of icariin in the low- to mid-micromolar range — Xin et al. 2003 (Asian J Androl, PMID 12646997) reported icariin IC50 ≈ 0.43 μM; subsequent reports in the 1–6 μM range across PDE5 isoforms. The Dell'Agli et al. 2008 J Nat Prod paper (PMID 18778098) found icariin IC50 ≈ 5.9 μM and showed that synthetic 3,7-bis(2-hydroxyethyl)icaritin reached IC50 ≈ 75 nM (close to sildenafil's ~74 nM). So: icariin itself is meaningfully weaker than sildenafil (low-mid μM vs ~74 nM = ~80× weaker), but synthetic icariin derivatives close the gap. Evidence: In Vitro, multiple replications, IC50 values vary by isoform / preparation.
Steroidogenic enhancement in Leydig cells — icariin at micromolar concentrations increases T production in rat and mouse Leydig cell preps. Evidence: Animal Model + In Vitro.
Bone density / osteoporosis indication — substantial Chinese RCT corpus for postmenopausal osteoporosis; not the indication of interest here but tangential evidence of real biological activity.
Mild aromatase modulation — proposed but not robust.

Chinese primary literature (CNKI / WanFang): - Multiple Chinese RCTs in erectile-dysfunction context report icariin / epimedium extracts improving subjective EF endpoints. T-elevation as a secondary endpoint is reported in some but not all. [VERIFICATION-PENDING — Sci-Hub mirrors checked 2026-05-07 (mirrors blocked); CNKI direct access required. Anna's Archive does not index relevant Chinese ED-RCT corpus. The PubMed-indexed English-language icariin RCT in ED that DOES exist: a 2013 Thai RCT (Thanakomsiri et al., n=61, IIEF-based, herbal-blend not pure icariin) — limited primary evidence base. Take-home: human RCTs of pure icariin in ED are scarce; the literature is dominated by mechanism papers (PDE5 IC50 work) and Chinese-language EF-endpoint trials of mixed-herb extracts. The "T-elevation as secondary endpoint" claim cannot be independently verified without CNKI access.] - Note: Hochu-ekki-to (補中益気湯) does NOT contain epimedium / yin-yang-huo as one of its 10 component herbs (its constituents include astragalus, ginseng, atractylodes, jujube, citrus peel, bupleurum, cimicifuga, glycyrrhiza, angelica, and Atractylodes/Pinellia depending on regional variant). The earlier draft's claim that Hochu-ekki-to "sometimes includes epimedium-equivalent yin-yang-huo" is incorrect. Epimedium is found in different Kampo / Chinese formulas (e.g., Erxian Tang 二仙汤, Zan Yu Dan) — not in Hochu-ekki-to. Corrected.

Bioavailability: - Icariin oral bioavailability is low (~3–12% reported across studies); microbiota convert icariin to icaritin (the more bioactive aglycone) in the gut. Standardized extracts increasingly target icaritin content rather than icariin content. - "Horny goat weed extract 50%" or "60%" labeling refers to total flavonoid content, not icariin content; standardization is industry-variable.

Safety: Generally well-tolerated. Theoretical PDE5-inhibition stacking with pharmacological PDE5 inhibitors (sildenafil, tadalafil) — would not combine. Vasodilatory side effects at high doses.

Dose: Standardized epimedium 500–1000 mg/d extract; targeting 20–40 mg icariin equivalent.

Cost: ~$15–30/month.

Gout-specific UA risk: Same caveat. Mild PDE5 inhibition has incidental microvascular benefit in gout (improved synovial perfusion, cleaner crystal clearance) — speculative but mechanistically interesting. Not the indication.

Verdict: In Vitro + Animal Model + Clinical Trial (Chinese ED literature). The PDE5 mechanism is the most distinctive and best-evidenced of this section. Reasonable adjuvant. Stacking note: do not combine with pharmacological PDE5 inhibitors.

5.3 Cordyceps sinensis / Cordyceps militaris (Dong Chong Xia Cao 冬虫夏草)¶

This compound is already covered in detail in the medicinal-mushroom-complement-track.md scope page, which treats cordyceps primarily through the urate / NLRP3 / ADA-inhibition lens. This section focuses ONLY on the cordyceps-T-axis evidence.

Active compounds (T-axis context): cordycepin (3'-deoxyadenosine), polysaccharides, ergosterol peroxide.

T-axis mechanism (proposed): - Cordycepin upregulates StAR and CYP11A1 in mouse Leydig cells, with downstream T elevation. Evidence: In Vitro + Animal Model. - Improved sperm count and motility in oligospermic men in small Chinese RCTs. Evidence: Clinical Trial (Chinese).

Chinese primary literature: Several CNKI papers report cordyceps supplementation modestly raising serum T in oligozoospermic men over 8–12 weeks. Effect sizes are modest (<20% T elevation typically). [VERIFICATION-PENDING — Sci-Hub mirrors blocked 2026-05-07; CNKI direct access required. PubMed-indexed counter-evidence worth noting: the only PubMed-indexed RCT of cordyceps supplementation in healthy young adults (8 weeks at 2.4 g/d C. sinensis) did not show significant testosterone elevation (Hsu et al. 2003 Life Sci — see Tu & Chen review PMC9333433). The "modest <20% T elevation in Chinese RCTs" claim is therefore not corroborated by the PubMed-indexed English-language RCT. Cross-reference medicinal-mushroom-complement-track.md for the cordyceps-and-UA evidence which has more rigorous primary citations and a more cautious overall T-elevation framing.]

Bioavailability: Cordycepin oral bioavailability is low — rapidly deaminated to 3'-deoxyinosine by adenosine deaminase. The whole-fermentate Cordyceps preparation includes natural pentostatin (an ADA inhibitor) that protects cordycepin from deamination (medicinal-mushroom-complement-track.md §"Whole-fermentate Cordyceps"). This is the relevant bioavailability-protection mechanism.

Dose: 1–3 g/d cordyceps extract; cordycepin content varies dramatically by preparation (wild O. sinensis very low; cultivated C. militaris much higher).

Cost: Very wide range. Wild O. sinensis is luxury-priced ($1000+/oz). Cultivated C. militaris is accessible ($30–80/month).

Gout-specific UA risk: Cordycepin is uniquely interesting — it has demonstrated URAT1 modulation in animal models (337 → 203 µmol/L SUA per medicinal-mushroom-complement-track.md). This is the rare T-axis adjuvant that is net UA-LOWERING in animal data. The T-elevation effect from cordyceps is modest, but the URAT1 modulation works in the opposite direction to the URAT1 upregulation that high T usually produces. Net effect is unknown but most favorable of the T-elevation candidates for the gout-comorbid case.

Verdict: The most gout-favorable T-axis adjuvant in this scan. Whole-fermentate C. militaris on brown rice (4–8 week home cycle, see medicinal-mushroom-complement-track.md) is the cleanest delivery. Cross-references the Open Enzyme platform thesis directly.

5.4 Cynomorium songaricum (Suo Yang 锁阳)¶

Active compounds: triterpenes, anthocyanins, gallic acid derivatives, flavonoids. Less chemically resolved than cistanche or epimedium.

Mechanism (proposed): - Anti-fatigue / "yang tonic" effects in rodent models. - Some evidence of testicular protection against oxidative stress.

Evidence base: Substantially weaker than cistanche, epimedium, or cordyceps. Most Chinese papers are open-label observational or animal-model.

Verdict: Not enough evidence to recommend over the other three TCM yang tonics in this section. Low priority for the scan.

5.5 Kampo formulas (Hochu-ekki-to / Hachimi-jio-gan)¶

Hochu-ekki-to (補中益気湯, "boost qi" formula) is a Kampo formula widely used in Japan for general fatigue / male hypogonadism / ED. It contains 10 herbs including astragalus, ginseng, atractylodes, jujube, citrus peel.

Japanese clinical evidence: - Tsujimura et al. 2010 (PMID 20143961, Aging Male "Clinical efficacy of Japanese traditional herbal medicine (Kampo) in patients with late-onset hypogonadism"). Note: the working-draft attribution "Tsukamoto 2002 / Tsujimura 2005" was incorrect on both author and year. The PubMed-indexed Tsujimura LOH-Kampo paper is 2010, not 2005. There is also an older paper by Ishikawa H. et al. 1992 (PMID 1519556, Am J Chin Med, "The hormonal response to HCG stimulation in patients with male infertility before and after treatment with hochuekkito") — n=63 infertile men, 7.5 g/d Hochuekkito × 3 months, sperm density and motility significantly increased, prolactin and E2 decreased, enhanced T and E2 response to hCG in oligoasthenoteratozoospermia. The wiki's older recall was conflating two different Japanese-andrology papers. Corrected. - The candidate Kampo formulas for LOH per the modern Japanese literature are Hochuekkito (TJ-41), Kamishoyosan (TJ-24), and Shakuyakukanzoto (TJ-68) (Tsumura formulations). Effect on T is real but smaller than TRT; AMS physical-symptom subscale tends to improve. - Hachimi-jio-gan (八味地黄丸, "rehmannia eight" formula) — older formula, similar indication, includes prepared rehmannia + cinnamon + aconite. Used in some Japanese geriatric urology contexts. Primary infertility paper: Miura, Matsuhashi et al. 1984 (PMID 6731200, Hinyokika Kiyo 30(1):97-102, in Japanese): n=53 men with male infertility treated with TSUMURA-Hachimijiogan 7.5 g/d for mean 144 days. Verified primary findings: sperm density improved in 22/53 (41.5%), sperm motility improved by ≥10% in 29/53 (54.7%), sperm motile efficiency index improved in 40/53 (75.5%). 4/53 wives (7.5%) conceived during treatment. Hormonal endpoint (separate paper, Usuki 1986 PMID 3083671, "Hachimijiogan changes serum hormonal circumstance and improves spermatogenesis in oligozoospermic men"): serum E2 increased; LH, FSH, prolactin, and testosterone showed no significant change. So the Hachimi-jio-gan effect on spermatogenesis is real but its testosterone-elevation effect in men is not supported — actually, T was UNCHANGED in the published hormonal endpoint study. [VERIFICATION CLOSED — Miura 1984 (PMID 6731200) and Usuki 1986 (PMID 3083671) confirmed via PubMed; the testosterone-elevation framing for Hachimi-jio-gan should be removed from the wiki; it's a spermatogenesis-improving formula but NOT a T-elevating formula in the primary literature.]

Bushi-zai (附子剤) — aconite-containing preparations used in Kampo for severe yang deficiency. Toxicology concern: raw aconitine is severely cardiotoxic; processed aconite (加工附子) is detoxified but not zero-risk. Not a self-experiment-friendly compound.

Translation note: Japanese Kampo papers typically use precise dosing language with formula-name standardization (Tsumura tablet doses are the most common reference). Translation across J-STAGE → English typically converges; substantial disagreement is rarer than in Chinese TCM corpus. [TRANSLATION-DISAGREEMENT ANTICIPATED low for Japanese Kampo; high for older Chinese TCM idioms.]

Verdict: Some clinical evidence in Japanese andrology literature for general fatigue and hypogonadal symptoms, but T-axis effect size is small and inconsistent. Not a primary candidate for the gout-comorbid SERM-user case.

5.6 Stacking note for the TCM section¶

Traditional Chinese formulas almost never use these herbs in isolation. Wu Zi Yan Zong Wan (五子衍宗丸) and Liu Wei Di Huang Wan (六味地黄丸) are formula-level prescriptions used in male reproductive / yang-tonic contexts. (Note: the actual single-herb composition of these formulas does not necessarily include all of cistanche / epimedium / cordyceps in any one formula — Wu Zi Yan Zong Wan's classical composition is the "five-seed" formula: Lycium barbarum, Cuscuta chinensis, Rubus chingii, Schisandra chinensis, Plantago asiatica. Liu Wei Di Huang Wan is the rehmannia-six base formula. The cistanche/epimedium combination appears in different formulas like Erxian Tang and Zan Yu Dan. The earlier draft over-claimed formula-level overlap.) Modern standardized extracts (Tsumura Kampo extracts, Chinese GMP suppliers) bridge traditional and modern. [VERIFICATION — partial follow-up 2026-05-07: a meta-analysis of Wu Zi Yan Zong Wan for oligoasthenozoospermia exists (PMC5822795) and the Hochu-ekki-to + Hachimi-jio-gan combination has a sperm-rescue paper in busulfan-induced aspermatogenesis (MDPI Int J Mol Sci 2020) — formula-level RCT evidence DOES exist for fertility endpoints, less so for primary T-elevation. Full systematic synthesis still pending; this section is now better-described as "formula-level RCT corpus exists for spermatogenesis indication but not for T-elevation primary endpoint."]

6. Enclomiphene (Clomid stereoisomer)¶

6.1 Pharmacology vs racemic clomiphene¶

Clomiphene citrate ("Clomid") is a 50:50 racemic mixture of two enantiomers:

Enclomiphene (E-isomer): pure ER-α antagonist at the hypothalamus. Short half-life (~10 hours). Drives the LH/FSH stimulation that produces endogenous T elevation.
Zuclomiphene (Z-isomer): mixed ER-α agonist/antagonist. Long half-life (~5–7 days, accumulates with chronic dosing). Produces the peripheral estrogenic activity that:
Raises SHBG (offsetting some Free T gain)
Causes mood / vision side effects in some men
Maintains some "estrogen-like" physiological tone

Clinical implication: racemic clomiphene's chronic-dosing pharmacology is dominated by zuclomiphene accumulation. Pure enclomiphene gives the LH-stimulation benefit without the long-half-life E-axis interference.

6.2 Current US availability and pricing (2026)¶

Pharmaceutical-grade enclomiphene (Androxal/Repros Therapeutics) — Repros Therapeutics developed enclomiphene specifically for secondary hypogonadism; submitted NDA to FDA; FDA issued a Complete Response Letter on December 1, 2015 stating that the Phase 3 study design was no longer adequate to demonstrate clinical benefit and recommending additional Phase 3 studies. The CRL also noted concerns about study entry criteria, dose titration, and bioanalytical method validation. Repros met with FDA's Division of Bone, Reproductive and Urologic Products in February 2016 to discuss the CRL. The required additional Phase 3 studies were never completed. Allergan acquired Repros in 2017; Androxal development was formally discontinued in 2021. [VERIFICATION CLOSED 2026-05-07 via Repros SEC press release / Fierce Biotech / GlobeNewswire — original draft's "FDA declined approval in 2016 AND 2017" was incorrect: the CRL was issued December 2015 (not 2016 or 2017); 2017 was the Allergan acquisition; 2021 was program shutdown. Corrected.]
Compounded enclomiphene — available via US telehealth/men's health clinics (Hone, Henry Meds, Ageless Mens Health, etc.) typically at $80–150/month for compounded product. Dosing typically 12.5–25 mg/d. Substantially cheaper than brand Clomid retail in markets where Clomid runs $150–250/month if compounded enclomiphene is available locally or via telehealth shipping.
Direct purchase from research-chemical suppliers — exists, not regulated; quality variable; not recommended.

6.3 Cleaner SHBG / E2 profile evidence¶

Wiehle 2013 (PMID 23875626, BJU International 112(8):1188-1200, PMC4155868): "Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study." Randomized, single-blind, two-center Phase II study. n=48 enrolled (intent-to-treat); 4 men had baseline T > 350 ng/dL excluded; n=44 completed per-protocol. Four arms: enclomiphene 6.25 / 12.5 / 25 mg/d, vs transdermal testosterone (AndroGel). Duration: 6 weeks continuous treatment, with single-dose pharmacokinetic profiling on day 1. Reported: enclomiphene increased serum total T into the normal range; concomitant increases in DHT and E2 without a corresponding rise in SHBG; LH and FSH preserved (vs suppressed by transdermal T). [VERIFICATION CLOSED — primary identifying details confirmed via PMC abstract and BJU citation.]
Wiehle 2014 (PMID 25044085, Fertility and Sterility 102(3):720-727): "Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone." Randomized Phase IIb. n=124 enrolled (73 completed per-protocol). This is the larger pivotal Phase II trial. Confirmed enclomiphene-driven T elevation comparable to topical T while preserving sperm count. [VERIFICATION CLOSED — sample size n=124 confirmed; specific SHBG and E2 effect-size deltas remain paywalled in full-text but the cleaner-than-clomiphene SHBG/E2 profile is the consistent finding across the Wiehle / Kim / Saffati corpus.]
Earl & Kim 2019 (PMID 31063005, Expert Rev Endocrinol Metab 14(3):157-165, doi:10.1080/17446651.2019.1612239): "Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism." Review article — synthesizes the Wiehle 2013 / 2014 / Kim 2016 corpus and the FDA NDA history. Consistent with the cleaner SHBG/E2 profile claim. [VERIFICATION CLOSED — citation now fully resolved; Earl JA / Kim ED, 2019 Expert Review journal.]
Saffati et al. 2024 (PMID 39434750, Translational Andrology and Urology, accepted 2024-08-16, published online 2024-09-24): "Safety and efficacy of enclomiphene and clomiphene for hypogonadal men." n=66 patients direct comparison. Enclomiphene → median T increase of 166 ng/dL (not statistically different from clomiphene). Estradiol change: −5.92 pg/mL on enclomiphene vs +17.50 pg/mL on clomiphene, P=0.001. Adverse events significantly less frequent with enclomiphene (decreased libido, reduced energy, mood changes); regression confirmed lower odds of AE on enclomiphene (P=0.02). Uric acid was NOT among the tracked endpoints in the published abstract. [VERIFICATION CLOSED — this is the paper the wiki had drafted as "Shin KH 2024," which appears to be a misattribution. Saffati / Kassab / Khera (Baylor College of Medicine) is the correct author group. The "Shin KH 2024" reference in androgen-urate-axis.md should be checked in that file's verification pass.]

6.4 Gout-specific UA risk¶

Same URAT1/ABCG2 mechanism as racemic clomiphene. The androgen is the driver; both formulations elevate androgen.
Open question whether enclomiphene's smaller E2 elevation produces a different net UA effect — estrogen is urate-lowering, so retaining more E2 elevation might offset some of the androgen-driven UA rise. Conversely, less E2 might mean a slightly larger net UA rise per unit T elevation. This is the unresolved question Shin KH 2024 may address.
No published study has directly compared UA changes on clomiphene vs enclomiphene at matched T elevation. Real research gap.

6.5 Verdict for the gout-comorbid SERM-user case¶

Enclomiphene is the most pharmacologically attractive of the SERM class for someone already taking and tolerating Clomid. Where telehealth access is feasible, switching from racemic clomiphene to enclomiphene is a higher-quality version of the same lever — cleaner SHBG / E2 / mood profile at potentially equivalent free-T outcome. Cost: $80–150/month compounded vs. $80–250/month brand-name Clomid depending on locale. The UA effect direction is unresolved but unlikely to be dramatically worse than racemic Clomid.

This is reframe #1 (lower-pharma + adjuvants) implemented at the Clomid/enclomiphene level rather than the herbal-adjuvant level.

7. Treatment-induced flare prophylaxis during UA-drop windows¶

This section addresses the specific mechanism that triggered the canonical motivating flare: UA-lowering interventions (whether pharmacological or via reduced T) cause crystal mobilization in the synovium, presenting clinically as a flare even though the long-run trajectory is favorable. ULT (urate-lowering therapy) initiation is the canonical context; a halved-Clomid step-down is mechanistically equivalent.

7.1 Colchicine prophylaxis — the gold standard¶

AGREE trial (Terkeltaub 2010, Arthritis Rheum 62:1060–1068, PMID 20131255) is an acute-flare-treatment trial (low-dose 1.8 mg total over 1 h vs high-dose 4.8 mg total over 6 h vs placebo for early acute gout); it is NOT a ULT-prophylaxis trial. Primary endpoint was 50%-pain-reduction-at-24-h: 28/74 (37.8%) low-dose, 17/52 (32.7%) high-dose, 9/58 (15.5%) placebo (P=0.005 vs placebo for low-dose). The AGREE result is what justifies the 1.2 mg + 0.6 mg-at-1-h acute-flare dosing in colchicine.md, not the prophylaxis dosing. The actual primary RCT for colchicine prophylaxis during ULT initiation is Borstad et al. 2004 (PMID 15570646, J Rheumatol 31(12):2429-2432): randomized double-blind placebo-controlled trial of colchicine 0.6 mg twice daily vs placebo during allopurinol initiation. Verbatim primary findings: colchicine arm experienced fewer total flares (0.52 vs 2.91, P=0.008), fewer flares 0–3 mo (0.57 vs 1.91, P=0.022), fewer flares 3–6 mo (0 vs 1.05, P=0.033), less severe flares (VAS 3.64 vs 5.08, P=0.018). Borstad established the 0.6 mg BID × 6 months prophylaxis discipline that the ACR 2020 guideline (PMID 32391934, FitzGerald et al.) carries forward.
Mechanism: dual-hit NLRP3 inhibitor (microtubule-driven ASC speck disruption at CP3 + P2X7 inhibition at CP2). Most fully evidenced flare prophylaxis intervention.
Effect size: in Borstad 2004 specifically, the absolute reduction was 0.52 vs 2.91 flares per patient over 6 months — an ~82% relative reduction in mean flare count, considerably larger than the "~50%" approximation in the original draft. A second RCT (n=200, "start low go slow" treat-to-target allopurinol, mean flares/month: 0.61 placebo vs 0.35 colchicine 0.5 mg/d) showed a smaller but still meaningful effect (~43% relative reduction). [VERIFICATION CLOSED — the original "~50%" was an over-rounded approximation; the actual primary literature shows a wider range (43–82%) depending on dosing and patient selection. The take-home that low-dose colchicine substantially reduces ULT-initiation flares is confirmed.]
Toxicity: narrow therapeutic index. CYP3A4 / P-glycoprotein interactions matter (statins, macrolides, calcium channel blockers). See colchicine.md for the full safety profile.
Cost: variable by locale. Generic colchicine ~$30–60/month at typical prophylaxis dose; brand-name Colcrys / Mitigare considerably more expensive in some markets.

For the Clomid-step-down case specifically: a 4–8 week course of low-dose (0.6 mg/d) colchicine prophylaxis during the dose-reduction window is the highest-evidence intervention for preventing the predictable mobilization flare during a UA-drop transition. Worth a physician conversation.

7.2 Curcumin¶

Mechanism: NLRP3 inhibition + NF-κB suppression + general anti-inflammatory.

Evidence: - Curcumin RCTs in gout: a small set of trials reports modest improvement. (a) Panahi et al. 2021 (PMID 32420786, J Diet Suppl): RCT of curcumin in asymptomatic hyperuricemia — found a trend toward serum-UA reduction vs placebo but NOT statistically significant (P=0.532). (b) Smaller open-label gout-cohort studies report SUA reduction (~528 → 422 μmol/L) and flare-frequency reduction (3.1 → 1.0/month) with curcumin 1000 mg/d × 12 wk. Systematic review across arthritis indications (Frontiers Immunol 2022) reports modest improvement at doses 120–1500 mg/d × 4–36 wk. Take-home: curcumin's anti-gout effect is plausible mechanistically but the RCT evidence base for serum-UA reduction is mixed and underpowered; the strongest claim is "modest CRP reduction" with weaker evidence for flare reduction in placebo-controlled designs. - Bioavailability is the central problem — native curcumin has <1% oral bioavailability. Formulations (Theracurmin, Meriva phytosome, Longvida, BCM-95) raise it 5–30×. - Critical caveat per supplement-abcg2-antagonism-computational.md: curcumin is a functional ABCG2 inhibitor at supplement doses, pharmacologically antagonizing the gut-lumen-sink thesis. For an Open Enzyme thesis-aligned patient, curcumin is a problematic flare-prophylaxis choice — it works on the inflammation arm but undermines the ABCG2-mediated UA excretion that is part of the long-term UA trajectory.

Verdict: Real anti-inflammatory effect; net unfavorable for the gout-comorbid case if the gut-lumen-sink mechanism matters to the patient. Other options below are mechanistically cleaner.

7.3 Omega-3 EPA/DHA¶

Mechanism: Substrate for SPM (specialized pro-resolving mediators — resolvins, protectins, maresins) — see spm-resolution-pathway.md. Competes with arachidonic acid for COX/LOX → reduces pro-inflammatory eicosanoid production.

Evidence: - Omega-3 in gout RCT — actual data is more pessimistic than the original draft. The pilot RCT (Stamp et al. 2022, PMID 35672866, BMC Rheumatol — n=40, 6.2 g/d omega-3 fish oil × 24 wk) found no statistically significant effect on serum UA (fish oil −0.021 ± 0.02 vs control −0.006 ± 0.02 mmol/L) AND no effect on gout flares (study underpowered for flare endpoint). What WAS significant: red-cell-omega-3 concentrations were inversely correlated with total flare count over weeks 12–24 (r = −0.75 to −0.76, P ≤ 0.001). An observational analysis (PMC6717014, Zhang et al. 2019) also found dietary fish-source omega-3 (NOT supplements) inversely associated with flare risk. Take-home: the supplement-form fish oil does not show a robust gout-flare-reduction effect in the RCT; the dietary-fish source does in observational data; the difference is unexplained. This is more cautious than the original draft. - Effect size: per the actual RCT, NOT meaningful for either flare reduction or SUA at supplemented doses. The "smaller than colchicine but still meaningful" framing in the prior draft was over-optimistic; the actual RCT data does not support it. Dietary-source-fish data is more favorable, and the SPM-mechanism hypothesis still holds for the cardioprotective indication. - Bioavailability: triglyceride-form fish oil > ethyl-ester form; krill > standard fish oil for some markers; Vascepa (icosapent ethyl, EPA-only) has cardiovascular RCT data (REDUCE-IT) but is pharmacologically branded.

Dose: 2–4 g/d combined EPA+DHA from fish oil. Higher doses → risk of mild bleeding (antiplatelet effect).

Cost: $20–40/month for reasonable-quality fish oil.

Gout-specific: Net UA-neutral; mildly favorable on inflammation arm. No ABCG2 antagonism concern. Stacks cleanly with the gut-lumen-sink thesis.

Verdict: The cleanest natural-product flare-prophylaxis adjuvant for the gout-comorbid case. Modest individual effect, no antagonism with the platform thesis, well-tolerated, cheap.

7.4 KPV peptide¶

See kpv-peptide.md for the full entry.

Mechanism: Tripeptide (Lys-Pro-Val) from C-terminus of α-MSH; inhibits NF-κB and modulates innate immune cell activation.

Evidence: Mostly animal model + emerging clinical (UC / IBD context). Gout-specific evidence: thin.

Availability: Research-peptide gray market; not pharmaceutically licensed for gout. Not appropriate for casual self-experimentation unless physician supervision.

7.5 Oridonin¶

See oridonin.md for the full entry.

Mechanism: Direct NLRP3 inflammasome inhibitor at CP2 (blocks ASC oligomerization).

Evidence: Strong In Vitro + Animal Model. No gout-specific human RCTs.

Availability: Research-grade. Not appropriate for casual self-experimentation. Listed for completeness — if the platform develops a delivery vehicle this could become relevant; today it is not the right tool for the casual flare-prophylaxis question.

7.6 Honest assessment of natural-product flare prophylaxis¶

Nothing matches colchicine's RCT evidence base for flare prophylaxis during UA-drop windows. This is not a controversial claim — it's the direct read of the AGREE trial and the ACR 2020 guideline. The natural-product layer:

Omega-3 EPA/DHA: real but smaller effect; clean stacking with the platform thesis. Reasonable adjuvant.
Curcumin: real anti-inflammatory effect but ABCG2-antagonism counterindication for the gut-lumen-sink-aligned patient.
KPV peptide / oridonin: research-stage; not appropriate for casual use.

The minimum-rigor honest stack for the gout-comorbid SERM-step-down case: low-dose colchicine prophylaxis (0.6 mg/d) for 4–8 weeks during the Clomid step-down + omega-3 EPA/DHA 2 g/d as a long-term layer. Curcumin should NOT be the first-line addition.

8. Recommended stack designs for the gout-comorbid case¶

The three reframes from §0, fleshed out as concrete protocols. These are research-stage options for self-experiment design discussion, not medical advice.

8.1 Reframe #1 — Lower-dose Clomid + adjuvants (probably highest-yield for the gout-comorbid case)¶

Pharmacology layer: - Halved Clomid dose (current state — already reduced by self-experiment). - OR switch to compounded enclomiphene 12.5 mg/d (cleaner SHBG / E2 profile; cost-neutral or cheaper than brand Clomid in PR).

Adjuvant layer: - Tongkat ali (Physta or LJ100) 200 mg/d — best-evidenced herbal free-T adjuvant; 10–30% modest effect. - Boron glycinate 5–10 mg/d — cheap; mechanism plausible; small evidence base. - Magnesium glycinate 200–400 mg/d elemental — deficiency-correction, mild uricosuric (favorable for gout). - Zinc picolinate 15–25 mg/d (with copper if prolonged) — deficiency-correction. - DIM 100–200 mg/d — E2-metabolism shift; complements Clomid's E2 elevation pattern.

Flare-prophylaxis layer: - Colchicine 0.6 mg/d for 4–8 weeks during dose transition (physician conversation). - Omega-3 EPA/DHA 2 g/d — long-term layer, no antagonism.

UA-management layer (the Open Enzyme cross-reference): - Fermentable fiber → butyrate → ABCG2 induction (per abcg2-modulators.md). - Avoid common ABCG2 inhibitors (curcumin, quercetin, EGCG at supplement doses) per the same page. - DO NOT layer high-fructose (per fructose-connection.md) — KHK pathway antagonizes everything else here.

8.2 Reframe #2 — Accept T-elevation, layer UA-counter-stack¶

If the self-experimenter's preference is to keep full Clomid and aggressively manage UA:

Pharmacology: full Clomid dose (status quo).

UA-counter-stack: - All of abcg2-modulators.md §"Inducer stack." - Carnosine 500–1000 mg/d (per carnosine.md — URAT1 / GLUT9 modulation, mirror-image mechanism to androgen-driven URAT1 upregulation). - Whole-fermentate C. militaris (cordyceps, per medicinal-mushroom-complement-track.md) — animal-model URAT1 modulation 337→203 µmol/L; the rare "T-axis adjuvant that is also UA-favorable." - Engineered uricase pipeline products (when available — uricase.md, koji-endgame-strain.md).

Flare prophylaxis: as in §8.1.

This is the platform-thesis-aligned reframe — the self-experimenter keeps the T benefit and uses the Open Enzyme platform thesis to manage the consequence.

8.3 Reframe #3 — Cycle on/off¶

Cleanest from a self-experiment-design perspective.

Cycling protocol: - 8–12 weeks on the chosen T-elevation lever (Clomid, enclomiphene, or tongkat ali stack). - 4–8 weeks off all T-elevation; UA recovers; provides within-subject baseline.

Measurements per self-experiment-protocol.md: - Total T, Free T, SHBG, E2, LH, FSH at start and end of each phase. - Uric acid + hs-CRP weekly during transitions. - Subjective tracking: libido, energy, mood, sleep, joint discomfort.

Advantages: - Within-subject controlled comparison. - Natural flare-risk dose-titration (UA peaks at on→off transitions are predictable). - Lets HPG axis recover during off phases.

Disadvantages: - Quality-of-life oscillation; not preferred by everyone. - The on→off transition is the predictable flare-risk window — colchicine prophylaxis specifically during these transitions.

9. Cost / availability landscape¶

Lever	Mechanism class	Cost/month (PR realistic)	Evidence tier	Gout-specific risk	Notes
Brand Clomid (50 mg/d)	SERM (HPG axis)	~$200	Clinical Trial (off-label)	Real UA elevation	Status quo; high cost
Generic clomiphene	SERM	~$30–60	Clinical Trial (off-label)	Real UA elevation	If accessible in PR
Compounded enclomiphene	SERM (cleaner)	~$80–150 (telehealth)	Clinical Trial	Same direction, possibly different magnitude	Best pharma alternative
Tongkat ali (Physta/LJ100)	SHBG displacement + cofactor + multi-target transporter modulation (URAT1↓ / GLUT9↓ / ABCG2↑ / NPT1↑) + PRPS-mediated purine-synthesis suppression	~$25–50	Clinical Trial (modest n)	Net UA-FAVORABLE (2021 RCT: SUA ↓7–11% at 100–200 mg/d × 12 wk)	Best-evidenced herbal; dual T-up + UA-down; mechanism corrected 2026-05-08 (XO claim was citation-laundering)
Fadogia agrestis	Steroidogenic (claimed)	~$15–30	Animal Model only + toxicity signal	Unknown; tox concern	NOT recommended
Boron glycinate	SHBG displacement (claimed)	~$5–10	One small RCT	Small UA risk if T rises	Cheap adjuvant
Magnesium glycinate	Deficiency correction	~$5–15	Established (deficiency)	Mildly UA-favorable	Measure status first
Zinc picolinate	Deficiency correction	~$5–10	Established (deficiency)	Small UA risk if T rises	Pair with copper if prolonged
DIM	E2 metabolism shift	~$15–25	In Vitro + small RCTs	Low	Cleaner with Clomid stack
Calcium D-glucarate	Estrogen excretion	~$15–30	In Vitro + small RCTs	Low	Adjuvant to DIM
Cistanche extract	TCM yang tonic	~$30–60	Clinical Trial (Chinese)	UA risk via T rise	CNKI evidence
Epimedium / icariin	PDE5 + steroidogenic	~$15–30	Animal + Chinese RCTs	UA risk via T rise	Don't combine with PDE5i
Cordyceps (whole-fermentate)	Steroidogenic + URAT1 modulation	~$30–80	Animal + Chinese RCTs	Net UA-favorable (URAT1 arm)	Best gout-comorbid choice
Cynomorium	Yang tonic	~$20–40	Animal Model	Unknown	Low priority
Hochu-ekki-to (Kampo)	Multi-herb formula	~$40–80	Japanese clinical	Unknown	Modest evidence
Colchicine 0.6 mg/d	NLRP3 (CP2/CP3)	~$30–60	Clinical Trial (RCT)	Anti-flare	First-line for flare prophylaxis
Omega-3 EPA/DHA 2g/d	SPM substrate	~$20–40	RCT meta-analysis	Mildly anti-flare; no antagonism	Cleanest natural adjuvant
Curcumin (high-bio formulation)	NLRP3 + NF-κB	~$30–60	RCT corpus	ABCG2 antagonist concern	Mechanistically problematic

10. Open questions / falsification-card-ready hypotheses¶

These are the explicit research gaps surfaced by this scan; format-compatible with the hypotheses/ H-card framework if any get prioritized:

H-AN-01: The enclomiphene-UA differential. No published study has directly compared serum UA changes on clomiphene vs enclomiphene at matched T elevation. Predicted direction unclear: enclomiphene's smaller E2 elevation could go either way relative to clomiphene's UA effect. Falsifiable via a 6-week within-subject crossover with the right serum panel. An on-Clomid self-experimenter switching to compounded enclomiphene is a plausible n=1 instance. (Cross-references androgen-urate-axis.md §Open questions; partial mechanistic frame in hypotheses/H07-clomid-intestinal-er-antagonism.md sub-claim 4 — H07's intestinal-ER-antagonism model predicts enclomiphene's UA effect direction depends on whether zuclomiphene's peripheral ER agonism rescues intestinal ER function in racemic Clomid.)

H-AN-08: The Clomid → high UA mechanism — formalized in H07. Promoted to its own falsification card 2026-05-07 — see hypotheses/H07-clomid-intestinal-er-antagonism.md. Brief: the long-observed clinical phenomenon "Clomid raises UA in gout-prone men" was historically attributed to direct AR-mediated suppression of intestinal ABCG2. comp-016 (T × intestinal ABCG2 evidence mining, 2026-05-07) found WEAK / UNCONFIRMED for that mechanism — zero in vivo studies show castration → intestinal ABCG2 ↑, and Klyushova 2023 actively contradicts the AR-suppression story. comp-017 (intestinal ABCG2 sex-dimorphism public-data mining, 2026-05-07) executed H07's Tier 0 killshot (GTEx + HPA + 4-paper full-text re-read) and concluded healthy-baseline intestinal ABCG2 sex-dimorphism is null or near-null, shifting the supported responder logic toward Q141K disease-state vulnerability rather than pan-male androgen suppression. Stack-design implication (highest-signal finding from the 2026-05-07 sweep per Pass 3): aromatase inhibitors and DIM become MORE unfavorable for SERM-using gout-comorbid men (they reduce E2 substrate for the intestinal ER → PI3K/Akt → ABCG2 induction pathway that Clomid is already blocking); direct urate-axis modulators (cordycepin, eurycomanone, butyrate) become MORE favorable (they bypass the ER pathway entirely). This contradicts the supplement-industry default and is reflected in the Androgen-elevated path of gout-action-guide.md. Cross-references comp-016, comp-017, and H07's full sub-claim status updates.

H-AN-02: Cordyceps as a uniquely gout-favorable T-axis adjuvant. Cordyceps cordycepin elevates T modestly (Chinese RCTs) AND modulates URAT1 in animal models (337→203 µmol/L). Predicted: net UA effect is favorable or neutral despite the T elevation. Falsifiable via a small comparative trial (cordyceps vs tongkat ali at matched T elevation, UA as primary endpoint). Plausibly the cleanest single-supplement test of the "T-up, UA-down via different mechanism" thesis. Cross-references medicinal-mushroom-complement-track.md.

H-AN-03: The boron-Naghii effect-size reproducibility. Naghii 2011 (n=8, 7 days, 10 mg/d) reported ~28% free-T elevation. The single small study has not been replicated in 14+ years despite being heavily cited. Falsifiable via a properly-powered (n=40+) 4–8 week RCT. Until done, the boron T-elevation claim should be treated as single small-n study, awaiting replication.

H-AN-04: Tongkat ali in eugonadal vs hypogonadal men. Meta-analytic signal suggests tongkat ali helps low-baseline T but has near-zero effect in eugonadal men. The supplement industry markets it indiscriminately. Falsifiable via baseline-T-stratified trial (probably already adequately tested in existing literature; needs a synthesis pull).

H-AN-05: The TCM yang tonic UA-tracking gap. No Chinese-language CNKI study of cistanche / epimedium / cordyceps has UA as a tracked endpoint despite all three being widely used in male hypogonadism contexts. Falsifiable via primary CNKI search and (if absent) a small prospective study tracking UA in men supplementing these. This is also a wiki coverage gap — the tcm-modern-rigor-intersection.md discipline could be applied to map T-elevation TCM herbs against UA risk specifically.

H-AN-06: Curcumin's ABCG2 antagonism in supplementing gout patients in vivo. Curcumin in vitro is an ABCG2 inhibitor; the in vivo magnitude at supplement doses with bioavailability-enhanced formulations is unclear. Cross-references supplement-abcg2-antagonism-computational.md. Falsifiable via direct ABCG2-activity assay in patient stool / serum on/off curcumin supplementation. Major decision-relevance for the Open Enzyme platform thesis.

H-AN-07: Pre-flare biomarker monitoring during UA-drop windows. The 2026-05-07 SERM-step-down case (logged in self-experiment-protocol.md) is canonical: a self-experiment ULT-equivalent step-down produced a predictable mobilization flare. What hs-CRP / IL-1β trajectory could have flagged the impending flare 24–48h before crystals mobilized clinically? Falsifiable in a prospective small-n self-experiment with daily hs-CRP. Adjacent to self-experiment-protocol.md.

11. Cross-references¶

androgen-urate-axis.md — the parent page; this page is its non-pharma alternative companion.
supplements-stack.md — generic NLRP3/UA compound catalog. Needs cross-reference update: tongkat ali, boron, DIM, cistanche, epimedium, cordyceps (T-axis context) are not currently entries; they belong in a "Section X: Hormonal Modulators" with the cross-link to this page.
self-experiment-protocol.md — measurement protocol; needs T/SHBG/E2 panel additions if absent.
abcg2-modulators.md — the UA-counter-stack mechanism cited throughout.
colchicine.md — the flare-prophylaxis gold standard.
oridonin.md, kpv-peptide.md — research-stage NLRP3 dampeners.
tcm-modern-rigor-intersection.md — discipline for evaluating TCM-lineage compounds.
medicinal-mushroom-complement-track.md — cordyceps detail; the gout-favorable T-adjuvant claim depends on this.
carnosine.md — URAT1/GLUT9 modulation; mirror-image to androgen-driven URAT1 upregulation.
fructose-connection.md — KHK pathway caveat for the dietary-carbohydrate SHBG-management discussion in androgen-urate-axis.md.
supplement-abcg2-antagonism-computational.md — the curcumin/quercetin/EGCG counterindication for ABCG2-aligned patients.
spm-resolution-pathway.md — omega-3 SPM mechanism for flare prophylaxis layer.

12. Verification status of this page¶

This page was authored 2026-05-07 as a multilingual literature scan in response to a specific self-experiment context (a halved-Clomid SERM-step-down flare logged in self-experiment-protocol.md). The first verification pass (PubMed-accessible papers) closed 11 markers and caught 11 specific factual errors — see operations/notable-moments.md 2026-05-07 entry. The second verification pass (this run, attempting Sci-Hub / Anna's Archive / direct OA for the database-access-bound markers) closed an additional batch of markers and produced one major substantive finding-tier update.

Second-pass verification status (2026-05-07):

Tongkat ali RCT effect sizes — George 2014, Talbott 2013, Tambi 2012, Henkel 2014: all CLOSED with primary-source-confirmed effect-size figures, sample sizes, dose, duration. The "37%" laundering pattern is fully characterized.
Tongkat ali UA effect — major substantive update. Original draft assumed UA-elevation via T-rise; second-pass primary-literature search found that tongkat ali Physta is actually UA-LOWERING in a 2021 placebo-controlled human RCT (n=105, SUA ↓7–11%). Mechanism corrected 2026-05-08 per comp-015 v2: multi-target transporter modulation (URAT1↓, GLUT9↓, ABCG2↑, NPT1↑) + PRPS-mediated purine-synthesis suppression (eurycomanol, PMID 34785103) — NOT xanthine oxidase inhibition (which was a supplement-industry citation-laundering artifact propagated through review-paper chains). See prps-purine-biosynthesis-chokepoint.md and t-axis-adjuvant-urate-mapping-computational.md (comp-015 v2). This reverses the §1.7 conclusion. Wiki verdict revised in §1.9 and §9 cost table. This is a finding-tier update, not just a verification close-out.
Boron Naghii 2011 — fully verified in first pass; UA-endpoint marker held as mechanistic-extrapolation tier (no primary boron-and-UA RCT exists).
Wiehle enclomiphene Phase II — CLOSED; correct citation is Wiehle 2013 BJU Int (n=48 dose-finding) AND Wiehle 2014 Fertility Steril (n=124 enrolled, 73 completed). Earl & Kim 2019 review citation also CLOSED.
"Shin KH 2024" enclomiphene paper — CLOSED via correction. The paper is Saffati et al. 2024 Translational Andrology and Urology (PMID 39434750), n=66 enclomiphene-vs-clomiphene head-to-head, NOT Shin KH. Estradiol delta verified: −5.92 vs +17.50 pg/mL, P=0.001. Uric acid was NOT a tracked endpoint. The cross-reference in androgen-urate-axis.md should be corrected separately.
FDA Repros action history — CLOSED. The original draft's "FDA declined approval in 2016 AND 2017" was wrong: actual sequence is December 2015 Complete Response Letter; February 2016 FDA meeting; 2017 Allergan acquisition; 2021 Androxal program shutdown. Corrected.
Fadogia testicular histopathology — REMAINS PENDING. International Scholars Journals paper is not PubMed-indexed and likely not retrievable via Sci-Hub/Anna's Archive (predatory/obscure publisher). Recommendation: drop the histopathology-specific framing in §2.3 and cite only the verified biochemical-marker testicular dysfunction finding (PMID 18023305).
Fadogia cardiac toxicity — REINTERPRETED. Yakubu 2008 Res J Med Plant lipid-profile paper (TG/LDL/HDL elevation) is the most likely source of the "cardiac toxicity" framing, NOT a direct cardiotoxicity study. Revise wiki language to "dyslipidemia in rat model with mechanistic concern for cardiovascular risk on chronic dosing."
CNKI cistanche / epimedium / cordyceps T-elevation trials — REMAIN PENDING. Sci-Hub mirrors are blocked at WebFetch level in this environment. Most CNKI papers don't have DOIs (Sci-Hub access impossible regardless). PubMed-indexed counter-evidence found for cordyceps: the only PubMed-RCT (8 wk, 2.4 g/d) did NOT show T elevation. Direct CNKI access is the actual blocker.
AGREE trial primary numbers + ULT prophylaxis effect size — CLOSED with major correction. AGREE is an acute-flare-treatment trial (NOT prophylaxis); the actual prophylaxis RCT is Borstad et al. 2004 (PMID 15570646): colchicine 0.6 mg BID vs placebo during allopurinol initiation, total flares 0.52 vs 2.91 (P=0.008) — ~82% relative reduction, considerably larger than the "~50%" approximation in the prior draft.
Magnesium uricosuric primary citation — CLOSED via correction. No primary RCT supports a "300–400 mg/d uricosuric" claim; only observational inverse association in cohorts (NHANES, Mendelian-randomization 2025). Tier revised from "small uricosuric effect" to "inverse observational association."
DIM testosterone-elevation in men — CLOSED with major correction. The published primary literature in men (BR-DIM in prostate cancer, PMC4759426) shows DIM has anti-androgenic activity — opposite direction from the supplement-industry T-elevation claim. Aksu 2016 male-rat study confirms DIM DECREASES T. This is a structural critique of §4 — the DIM-as-T-booster framing should be substantially revised; DIM is appropriate as an estrogen-metabolism shifter, not a T-elevation lever.
Hochu-ekki-to / Hachimi-jio-gan — CLOSED. Miura 1984 (PMID 6731200) verified for spermatogenesis improvement; Usuki 1986 (PMID 3083671) verified for hormonal endpoints — and shows testosterone was UNCHANGED in oligozoospermic men. The "Hachimi-jio-gan T-elevation" framing should be removed.
DIM × allopurinol PK interaction — CLOSED partial. DIM is a PXR activator → CYP1A2 / CYP3A4 induction (Sun et al. 2015; Hwang 2016). Allopurinol's primary metabolic route is XO/AO, not these CYPs, so direct PK interaction is mechanistically less likely than initially framed.

Markers still PENDING after second-pass attempt: - Fadogia testicular histopathology (predatory-publisher access — likely unfixable) - CNKI Chinese RCT corpus for cistanche / epimedium / cordyceps (no DOI access — direct CNKI required) - Bahasa-Malaysia FRIM repository papers (low load-bearing for §1.2 conclusions)

This page is now substantively verified at the load-bearing-claim tier. The tongkat-ali UA-direction reversal is the most decision-relevant update and propagates to §1.7, §1.9, §9, and the §10 hypothesis cards.